Skip to Content

Silodosin (Rapaflo) for Benign Prostatic Hyperplasia

Silodosin (Rapaflo - Watson Pharmaceuticals), an alpha1a-adrenoreceptor selective antagonist, has been approved by the FDA for treatment of benign prostatic hyperplasia (BPH). Some medications for BPH are listed in the table on page 4. Alpha1 blockers are commonly used with 5a-reductase inhibitors such as finasteride, which can shrink the size of the prostate, but may take months to do so....
Cannot Access - We are sorry, but you cannot access the requested article.
login now
login now
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Silodosin (Rapaflo) for Benign Prostatic Hyperplasia
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1303
Article Code: 1303c
Date: January 12, 2009
Volume: 51
Pages: 3-4

 Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article.
 Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article.